Yoshimasa Imoto

Dr. Yoshimasa Imoto

Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
YIYoshimasa Imoto
Yoshimasa Imoto
TTTetsuji Takabayashi
Tetsuji Takabayashi
MSMasafumi Sakashita
Masafumi Sakashita
YKYukinori Kato
Yukinori Kato
KYKanako Yoshida
Kanako Yoshida
SFShigeharu Fujieda
Shigeharu Fujieda
Background: The pathological features of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) tissues include an eosinophilic infiltration pattern (eosinophilic CRS (ECRS)) or a less eosinophilic pattern (non-ECRS). Recently, it has been suggested that 15-lipoxygenase 1 (15-LOX-1) may have significant roles in allergic disease; however, the significance of 15-LOX-1 in CRS is not well understood. The objective of this study was to demonstrate the expression of 15-LOX-1 in CRS. Methods: The mRNA expression levels of 15-LOX-1 and periostin in nasal tissues were measured by quantitative real-time polymerase chain reaction. We also performed an immunofluorescence study of nasal tissues. Cells of the Eol-1 eosinophilic leukemic cell line were stimulated with interleukin-33 to test the induction of 15-LOX-1. Results: The expression level of 15-LOX-1 mRNA in nasal polyps (NPs) was significantly higher in ECRS patients than in non-ECRS patients. The immunofluorescence study revealed that both airway epithelial cells and eosinophils in NPs expressed 15-LOX-1. A significant correlation was seen between the number of eosinophils and the mRNA expression levels of 15-LOX-1 and periostin in nasal polyps. Moreover, interleukin-33 enhanced 15-LOX-1 expression in Eol-1 cells. Conclusions: 15-LOX-1 was shown to be a significant molecule that facilitates eosinophilic inflammation in ECRS.

1 December 2019 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
YIYoshimasa Imoto
Yoshimasa Imoto
AKAtsushi Kato
Atsushi Kato
TTTetsuji Takabayashi
Tetsuji Takabayashi
WSWhitney Stevens
Whitney Stevens
JNJames E. Norton
James E. Norton
RSRobert P. Schleimer
Robert P. Schleimer

31 August 2010 in Acta Oto-Laryngologica
Verified
Journal Article
Closed access
PDF file
YIYoshimasa Imoto
Yoshimasa Imoto
AKAkihiro Kojima
Akihiro Kojima
YOYouko Osawa
Youko Osawa
HSHiroshi Sunaga
Hiroshi Sunaga
SFShigeharu Fujieda
Shigeharu Fujieda
Conclusions: We conclude that the capsaicin inhalation test is useful to directly assess cough reflex and sensation around the larynx, while it indirectly reflects central nervous system function. Objectives: To understand the state of the cough reflex before patients with dysphagia start eating. Methods: We studied the cough reflex by the capsaicin inhalation test in 21 patients with dysphagia and 12 healthy persons without dysphagia. Results: The control group showed a cough reflex at a capsaicin concentration of 2.61 μM (0.98–7.80), while patients with mild dysphagia did so at 7.28 μM (1.95–15.6), those with moderate dysphagia at 22.07 μM (15.6–62.5), and those with severe dysphagia at 71.75 μM (31.2–250). Control vs mild p < 0.01, control vs moderate p < 0.01, control vs severe p < 0.01, mild vs moderate p < 0.01, mild vs severe p < 0.01, moderate vs severe p < 0.05. There was a significant correlation between the grade of dysphagia and the threshold capsaicin concentration that provoked a cough reflex (ρ = –0.796, p < 0.001).

3 January 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YIYoshimasa Imoto
Yoshimasa Imoto
SUShigeharu Ueki
Shigeharu Ueki
YKYukinori Kato
Yukinori Kato
KYKanako Yoshida
Kanako Yoshida
TMTaiyo Morikawa
Taiyo Morikawa
SFShigeharu Fujieda
Shigeharu Fujieda
Background: Eosinophilic chronic sinusitis (ECRS) is a subtype of CRS with nasal polyps (CRSwNP) that is frequently comorbid with asthma. Notably, ECRS patients often show a high recurrence of NPs after surgical resection. Leptin is a hormone produced by adipocytes that has been implicated in airway inflammatory diseases. However, to date, the role of leptin in ECRS has not been investigated.Objective: To determine whether the serum levels of leptin are altered in patients with ECRS.Methods: In total, 40 patients with ECRS, 15 patients with non-eosinophilic CRS (non-ECRS), and 12 individuals without CRS (control) were included in this study. Patient’s serum leptin levels were assessed, and the number of eosinophils in their NPs were measured through a histological evaluation of the three densest areas with cellular infiltrate beneath the epithelial surface. Finally, nasal fibroblast cultures established from NPs were stimulated with varying concentrations of recombinant leptin in vitro to determine whether leptin affects eotaxin-3 (Chemokine (C-C motif) ligand 26 :26: CCL26) expression.Results: The serum leptin levels in both the ECRS and non-ECRS groups were significantly higher than those in the control subjects (p < 0.0001 vs. ECRS; p < 0.05 vs. non-ECRS). Furthermore, ECRS patients displayed significantly elevated serum leptin levels compared to non-ECRS patients (p < 0.001), although there was no difference in body mass index between the groups. Notably, serum leptin levels were correlated with the proportion of eosinophils in peripheral blood (r = 0.3575, p < 0.01) and the number of eosinophils in NPs (r = 0.5109, p < 0.0001). Serum leptin levels were also correlated with eotaxin-3 mRNA expression in NPs (r = 0.5374, p < 0.01). Finally, leptin significantly augmented eotaxin-3 expression in nasal fibroblasts established in vitro from NPs in a leptin receptor-dependent manner (p < 0.05).Conclusion: Leptin levels are elevated in ECRS patients and may both promote and indicate the severity of ECRS as well as systemic type 2-biased inflammatory responses. Combined, these data indicate that circulating leptin may play a significant role in the development of eosinophilic inflammation in NPs.

15 July 2025 in Cancer Treatment Reviews
Verified
Journal Article
Open access
MKMasafumi Kanno
Masafumi Kanno
SKSatoshi Kano
Satoshi Kano
YIYoshinori Imamura
Yoshinori Imamura
DKDaisuke Kawakita
Daisuke Kawakita
Norihiko NaritaNorihiko Narita
Norihiko Narita
SFShigeharu Fujieda
Shigeharu Fujieda
Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy of the salivary glands. For patients ineligible for curative surgery or definitive radiotherapy, treatment options remain limited owing to the absence of standardized therapeutic protocols. This review draws upon major salivary gland cancer guidelines and integrates molecular profiles with clinical response data to propose an evidence-based treatment algorithm that stratifies patients into four groups according to the expression status of human epidermal growth factor receptor 2 (HER2) and androgen receptor (AR). In HER2-positive tumors, HER2-targeted therapy constitutes the standard of care, with trastuzumab plus docetaxel providing clinical benefit. Antibody-drug conjugates, such as trastuzumab deruxtecan, have demonstrated efficacy even in patients with disease progression during trastuzumab-based therapy. In AR-positive tumors, androgen deprivation therapy, particularly combined androgen blockade, has demonstrated clinical activity, though concurrent molecular characteristics may influence treatment outcomes. In HER2-positive/AR-positive tumors, HER2-targeted therapy is generally prioritized, although the absence of validated predictive biomarkers and defined thresholds remains a clinical challenge. For HER2-negative and AR-negative tumors, or those refractory to either or both targeted approaches, cytotoxic chemotherapy remains a viable option. Immune checkpoint inhibitors may offer benefits in tumors with high PD-L1 expression, although data on their role in SDC remain limited. Next-generation sequencing is recommended to identify actionable alterations (e.g., NTRK, BRAF, FGFR, HRAS) that may guide targeted therapy or clinical trial enrollment. Integrating comprehensive molecular profiling into treatment decision-making is essential to optimizing outcomes in advanced SDC.

26 June 2015 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
YIYoshimasa Imoto
Yoshimasa Imoto
TTTetsuji Takabayashi
Tetsuji Takabayashi
MSMasafumi Sakashita
Masafumi Sakashita
TTTakahiro Tokunaga
Takahiro Tokunaga
TNTakahiro Ninomiya
Takahiro Ninomiya
SFShigeharu Fujieda
Shigeharu Fujieda
Measuring specific IgE can yield direct, accurate, and objective data. Nevertheless, clinical symptoms of allergy are often inconsistent with these data. Recently, the expression of CD203c, a surface marker of basophils, has been reported as capable of distinguishing allergic patients. This study compared specific IgE in serum and skin tests against antigen to assess CD203c as a biomarker correlated with allergic rhinitis (AR). We asked 3,453 subjects whether they experienced any AR related symptom. All subjects were assessed for six specific IgEs for common aeroallergens. Skin tests were also conducted for six aeroallergens. We observed the reactivity of peripheral basophil by measuring the levels of CD203c by Cryj1 stimulation using flow cytometry. Of the 3,453 participants, 1,987 (57.5%) possessed Japanese cedar pollen (JCP) specific IgE in their serum. Among those 1,987 JCP specific IgE positive participants, 552 (27.8%) had not experienced any allergic symptom during the JCP season. The levels of CD203c in the peripheral basophil by Cryj1 stimulation were significantly higher in SAR‐JCP subjects than in non‐SAR‐JCP subjects (Cryj1 0.5 ng/ml: 2.25 ± 0.90% vs. 60.2 ± 27.4%, p < 0.01, Cryj1 50 ng/ml: 1.89 ± 0.90% vs. 68.0 ± 21.2%, p < 0.01). Our results indicate that the levels of CD203c in peripheral basophils by Cryj1 stimulation is a more objective and reliable marker that better reflects the allergic reaction by SAR‐JCP in vivo than measuring specific IgE in serum or skin tests.